<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-0807</journal-id>
<journal-title><![CDATA[Revista de la Universidad Industrial de Santander. Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Univ. Ind. Santander. Salud]]></abbrev-journal-title>
<issn>0121-0807</issn>
<publisher>
<publisher-name><![CDATA[Universidad Industrial de Santander]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-08072023000100064</article-id>
<article-id pub-id-type="doi">10.18273/saluduis.55.e:23018</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Factores relacionados a flebitis química en personas con quimioterapia, revisión sistemática de la literatura]]></article-title>
<article-title xml:lang="en"><![CDATA[Factors related to chemical phlebitis in patients treated with chemotherapy, a systematic literature review]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sierra-Calderón]]></surname>
<given-names><![CDATA[Lizeth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Millán-Quijano]]></surname>
<given-names><![CDATA[Viviana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Becerra-Orozco]]></surname>
<given-names><![CDATA[Jennifer]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez Tovar]]></surname>
<given-names><![CDATA[Luz Omaira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Laboratorio Procaps  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro de tratamiento e investigación sobre Cáncer  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Asisfarma S.A.S  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad Surcolombiana  ]]></institution>
<addr-line><![CDATA[Neiva ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<volume>55</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-08072023000100064&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-08072023000100064&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-08072023000100064&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Describir los factores asociados a la flebitis química en personas con diagnóstico de cáncer que reciben quimioterapia, evidenciados en la literatura.  Metodología: Se realizó una revisión sistemática de la literatura, según recomendaciones de Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA).  Resultados: Los factores que aumentaron el riesgo de flebitis química hallados en la evidencia fueron la edad mayor de 57 años, sexo femenino, antecedentes de cáncer, enfermedad metastásica, hipertensión arterial, neutropenia, tabaquismo, vaciamiento ganglionar, hipoalbuminemia, uso de medicamentos citotóxicos, epirrubicina, fosaprepitant, antraciclina y vinorelbina, presentación premezclada de los fármacos, dilución en 50 cc de solución salina normal, tiempo de administración mayor a 60 minutos, catéteres de calibres grandes como 18 G o 20 G y ubicación anatómica del catéter en antebrazo o fosa antecubital.  Conclusión: los factores relacionados a la flebitis química hallados en la literatura fueron principalmente elementos inherentes al paciente y a su tratamiento, algunos de estos no son modificables.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To describe the factors related to chemical phlebitis in patients diagnosed with cancer undergoing chemotherapeutic treatment.  Methodology: A systematic review of the literature was carried out, according to recommendations of Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA).  Results: The factors that increase the risk of chemical phlebitis were: age older than 57 years, female sex, history of cancer, metastatic disease, arterial hypertension, neutropenia, smoking, lymph node emptying, hypoalbuminemia, use of cytotoxic drugs, epirubicin, fosaprepitant, anthracycline and vinorelbine, premixed presentation, dilution in 50 cc of Normal Saline Solution, administration time greater than 60 minutes, catheters of large gauges such as 18 G or 20 G and anatomical location of the catheter in the forearm or antecubital fossa.  Conclusion: Factors related to chemical phlebitis found in the literature were features inherent to the patient and their treatment. Therefore, some of these are not modifiable.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Flebitis]]></kwd>
<kwd lng="es"><![CDATA[Factores de riesgo]]></kwd>
<kwd lng="es"><![CDATA[Neoplasias]]></kwd>
<kwd lng="es"><![CDATA[Tratamiento farmacológico]]></kwd>
<kwd lng="es"><![CDATA[Quimioterapia]]></kwd>
<kwd lng="en"><![CDATA[Phlebitis]]></kwd>
<kwd lng="en"><![CDATA[Risk factors]]></kwd>
<kwd lng="en"><![CDATA[Neoplasms]]></kwd>
<kwd lng="en"><![CDATA[Drug therapy]]></kwd>
<kwd lng="en"><![CDATA[Chemotherapy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santiago-Valverde]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relación entre conocimiento y práctica sobre cateterismo venoso periférico en los enfermeros de hospitalización de medicina general del Hospital Nacional Hipólito UNANUE]]></article-title>
<source><![CDATA[Rev. peru. obstet. enferm]]></source>
<year>2012</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>10-22</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bulechek]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Butcher]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Dochterman]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<source><![CDATA[CMW. Clasiicación de Intervenciones de Enfermería (NIC)]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Athanasio Johann]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Reichembach Danski]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Adami Vayego]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aparecida Barbosa]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lind]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores de riesgo para complicaciones en el catéter periférico en adultos: análisis secundario de ensayo clínico aleatorizado]]></article-title>
<source><![CDATA[Rev Lat Am Enfermagem]]></source>
<year>2016</year>
<numero>24</numero>
<issue>24</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gorski]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hadaway]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hagle]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[McGoldrick]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Orr]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Doellman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infusion therapy standards of practice]]></article-title>
<source><![CDATA[J Infus Nurs]]></source>
<year>2016</year>
<volume>39</volume>
<numero>^s1S</numero>
<issue>^s1S</issue>
<supplement>1S</supplement>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<collab>National Cancer Institute, National Institutes of Health, Departement of Health &amp; Human Services - USA</collab>
<source><![CDATA[The NCI Consumers' Cancer Dictionary for peer review]]></source>
<year>2009</year>
<page-range>79</page-range><publisher-loc><![CDATA[Bethesda (MD) ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Becerra]]></surname>
<given-names><![CDATA[ÁG]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno Pinilla]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Sarmiento Hernández]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Evaluación del procedimiento de administración de medicamentos endovenosos y la presencia de lebitis química en el servicio de hospitalización de la Clínica Foscal Internacional durante el año 2015]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Medellín ]]></publisher-loc>
<publisher-name><![CDATA[Universidad CES]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alonso Delgado]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[García Díaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[González Andrés]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Gestión de calidad en la prevención de lebitis en el servicio de Oncología del HUBU]]></source>
<year>2017</year>
<page-range>37</page-range><publisher-loc><![CDATA[Burgos ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Burgos]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rojas-Sánchez]]></surname>
<given-names><![CDATA[LZ]]></given-names>
</name>
<name>
<surname><![CDATA[Parra]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
<name>
<surname><![CDATA[Camargo-Figuera]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidencia y factores asociados al desarrollo de flebitis: resultados del estudio piloto de una cohorte]]></article-title>
<source><![CDATA[Rev Enferm Ref]]></source>
<year>2015</year>
<volume>IV</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>61-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Núñez Crespo]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Efectos adversos hospitalarios en dispositivos venosos periféricos: Estudio de validez diagnóstica]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Rey Juan Carlos]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reichembach]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Athanasio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Adami]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Paulo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Complicações relacionadas ao uso do cateter venoso periférico: ensaio clínico randomizado]]></article-title>
<source><![CDATA[Acta Paul Enferm]]></source>
<year>2016</year>
<volume>29</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>84-92</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaca Auz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz Navarro]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eventos adversos relacionados con los cuidados de enfermería en el Hospital de Ibarra, provincia de Imbabura]]></article-title>
<source><![CDATA[Enferm. investig]]></source>
<year>2016</year>
<volume>1</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>102-6</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz-Ríos]]></surname>
<given-names><![CDATA[GV]]></given-names>
</name>
<name>
<surname><![CDATA[Quispe-Cóndor]]></surname>
<given-names><![CDATA[SZ]]></given-names>
</name>
<name>
<surname><![CDATA[Sovero-Torres]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
<name>
<surname><![CDATA[Pando-Berrocal]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Flebitis: incidencia y factores asociados en pacientes oncológicos]]></article-title>
<source><![CDATA[Rev Cienc Art Enferm]]></source>
<year>2019</year>
<volume>4</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>6-11</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pires Nobre]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[da Silva Martins]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalência de flebite da venopunção periférica: fatores associados]]></article-title>
<source><![CDATA[Rev Enferm Ref]]></source>
<year>2018</year>
<volume>IV</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>127-38</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velázquez-Mendoza]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Alonso]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cuamatzi-Peña]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Izquierdo-Puente]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Conocimiento y criterios de enfermería para evitar flebitis en neonatos con catéter venoso periférico]]></article-title>
<source><![CDATA[Rev Enferm Inst Mex Seguro Soc]]></source>
<year>2009</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>143-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lv]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The incidence and risk of infusion phlebitis with peripheral intravenous catheters: A meta-analysis]]></article-title>
<source><![CDATA[J Vasc Access]]></source>
<year>2020</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>342-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Contreras Carpio]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<source><![CDATA[Factores cognitivos, físicos y químicos asociados con la presencia de lebitis en pacientes atendidos por enfermeros HNERM - 2012]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Lima ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional Mayor de San Marcos]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urbanetto]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Freitas]]></surname>
<given-names><![CDATA[APC]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[APR]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[JCR]]></given-names>
</name>
<name>
<surname><![CDATA[Muniz]]></surname>
<given-names><![CDATA[FOM]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for the development of phlebitis: an integrative review of literature]]></article-title>
<source><![CDATA[Rev Gaúcha Enferm]]></source>
<year>2017</year>
<volume>38</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monteros Cocios]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[González Cartuche]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
</person-group>
<source><![CDATA[Flebitis por manejo de catéter venoso periférico en pacientes atendidos en el área de quimioterapia del hospital de Solca Loja]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Loja ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional de Loja]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Navarrete Ruíz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Factores que influyen en la aparición de lebitis química en pacientes hospitalizados en el área de oncología del hospital de Especialidades FF.AA. No1, octubre 2018-abril 2019]]></source>
<year>2019</year>
<publisher-name><![CDATA[Universidad "Técnica de Babahoyo"]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alcalde Berganza]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Flebitis en catéter venoso periférico: Factores de riesgo y prevención]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Bilbao ]]></publisher-loc>
<publisher-name><![CDATA[Universidad del País Vasco]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<collab>Ministerio de salud y protección social de Colombia</collab>
<source><![CDATA[Evaluación de la frecuencia de eventos adversos y monitoreo de aspectos claves relacionados con la seguridad del paciente]]></source>
<year>2014</year>
<volume>2</volume>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Minsalud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud y Protección Social de Colombia</collab>
<source><![CDATA[Seguridad del paciente y la atención segura]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Minsalud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guillén Ponce]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Molina Garrido]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Qué es, cómo funciona y tipos de quimioterapia]]></source>
<year>2019</year>
<page-range>20</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Sociedad Española de Oncología Médica]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="book">
<collab>Fondo Colombiano de Enfermedades de Alto Costo, (CAC) C de AC</collab>
<source><![CDATA[Situación del cáncer en la población adulta atendida en el SGSSS de Colombia 2020]]></source>
<year>2021</year>
<page-range>332</page-range><publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Cuenta de Alto Costo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<collab>American Cancer Society</collab>
<source><![CDATA[Cancer Treatment and Survivorship Facts and Figures 2019-2021]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Atlanta ]]></publisher-loc>
<publisher-name><![CDATA[American Cancer Society]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="book">
<collab>American Cancer Society</collab>
<source><![CDATA[Cancer Facts &amp; Figures 2020]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Atlanta ]]></publisher-loc>
<publisher-name><![CDATA[American Cancer Society]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreiro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Barceló]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quimioterapia: efectos secundarios]]></article-title>
<source><![CDATA[Gac Medica Bilbao]]></source>
<year>2003</year>
<numero>100</numero>
<issue>100</issue>
<page-range>69-74</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruíz-Morales]]></surname>
<given-names><![CDATA[ÁJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Restrepo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Epidemiología Clínica]]></source>
<year>2015</year>
<edition>2a</edition>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Panamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guirao Goris]]></surname>
<given-names><![CDATA[SJA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilidad y tipos de revisión de literatura]]></article-title>
<source><![CDATA[Ene]]></source>
<year>2015</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>14</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Liberati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tetzlaff]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2009</year>
<numero>339</numero>
<issue>339</issue>
<page-range>b2535</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Estarli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar Barrera]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Rodríguez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Baladia]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Duran Agüero]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Camacho]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ítems de referencia para publicar Protocolos de revisiones sistemáticas y metaanálisis: Declaración PRISMA-P 2015]]></article-title>
<source><![CDATA[Rev Esp Nutr Hum Diet]]></source>
<year>2016</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>148</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grant]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Booth]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A typology of reviews: An analysis of 14 review types and associated methodologies]]></article-title>
<source><![CDATA[Health Info Libr J]]></source>
<year>2009</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>91-108</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yamada]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Egashira]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nagata]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yano]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nonaka]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Decrease in the vinorelbine-induced venous irritation by pharmaceutical intervention]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2012</year>
<volume>20</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1549-53</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arias-Fernández]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Suérez-Mier]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Ortega M del]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lana]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and risk factors of phlebitis associated to peripheral intravenous catheters]]></article-title>
<source><![CDATA[Enfermería Clínica]]></source>
<year>2017</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>79-86</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Kadakia]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Looker]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hilger]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sorgatz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fosaprepitant-induced phlebitis: A focus on patients receiving doxorubicin/cyclophosphamide therapy]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2014</year>
<volume>22</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1313-7</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hegerova]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Grendahl]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Seisler]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Sorgatz]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2015</year>
<numero>23</numero>
<issue>23</issue>
<page-range>55-9</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hanna]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Borley]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dolan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epirubicin chemotherapy in women with breast cancer: Alternating arms for intravenous administration to reduce chemical phlebitis]]></article-title>
<source><![CDATA[Eur J Cancer Care (Engl)]]></source>
<year>2019</year>
<numero>00</numero>
<issue>00</issue>
</nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonçalves]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Sanches]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Bueno]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Villela de Castro]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Damascena]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[GRC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of infusion site reactions in peripheral fosaprepitant infusions]]></article-title>
<source><![CDATA[J Infus Nurs]]></source>
<year>2017</year>
<volume>40</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>380-3</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Capucho Rodrigues]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Guilherme]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lobo da Costa Júnior]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Campos de Carvalho]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fatores de risco para trauma vascular durante a quimioterapia antineoplásica: contribuições do emprego do risco relativo]]></article-title>
<source><![CDATA[Acta Paul Enferm]]></source>
<year>2012</year>
<volume>25</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>448-52</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagata]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Egashira]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yamada]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yamauchi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Oishi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Change of formulation decreases venous irritation in breast cancer patients receiving epirubicin]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2012</year>
<volume>20</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>951-5</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zou]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of vinorelbine plus cisplatin vs. gemcitabine plus cisplatin for treatment of metastatic triple-negative breast cancer after failure with anthracyclines and taxanes]]></article-title>
<source><![CDATA[Med Sci Monit]]></source>
<year>2017</year>
<numero>23</numero>
<issue>23</issue>
<page-range>4657-64</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mestre Roca]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Berbel Bertolo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Tortajada Lopez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gallemi Samaranch]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar Ramirez]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Caylà Buqueras]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing the influence of risk factors on rates and dynamics of peripheral vein phlebitis: An observational cohort study]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2012</year>
<volume>139</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>185-91</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wallis]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[McGrail]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Webster]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Marsh]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gowardman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Playford]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for peripheral intravenous catheterfailure: Amultivariate analysis of data from a randomized controlled trial]]></article-title>
<source><![CDATA[Infect Control Hosp Epidemiol]]></source>
<year>2014</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>63-8</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mandal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[K]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Study on incidence of phlebitis following the use of pherpheral intravenous catheter.]]></article-title>
<source><![CDATA[J Fam Med Prim Care]]></source>
<year>2019</year>
<numero>8</numero>
<issue>8</issue>
<page-range>2827-31</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nyika]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Mukona]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zvinavashe]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors Contributing to Phlebitis among Adult Patients Admitted in the Medical-Surgical Units of a Central Hospital in Harare, Zimbabwe]]></article-title>
<source><![CDATA[J Infus Nurs]]></source>
<year>2018</year>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>96-102</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Milutinovic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Simin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zec]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factor for phlebitis: A questionnaire study of nurses' perception]]></article-title>
<source><![CDATA[Rev Lat Am Enfermagem]]></source>
<year>2015</year>
<volume>23</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>677-84</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[do Rego Furtado]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and predisposing factors of phlebitis in a surgery department]]></article-title>
<source><![CDATA[Br J Nurs]]></source>
<year>2011</year>
<volume>20</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>S16-25</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Atay]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Çukurlu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phlebitis-related peripheral venous catheterization and the associated risk factors]]></article-title>
<source><![CDATA[Niger J Clin Pract]]></source>
<year>2018</year>
<numero>21</numero>
<issue>21</issue>
<page-range>827-31</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saito]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshizawa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshimori]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Katakami]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Katsumata]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kawahara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: A multicentre, randomised, double-blind, placebo-controlled phase 3 trial]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2013</year>
<numero>24</numero>
<issue>24</issue>
<page-range>1067-73</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yamasaki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kimura]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mayahara]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Maeda]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nishida]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant]]></article-title>
<source><![CDATA[Mol Clin Oncol]]></source>
<year>2019</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>43-9</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pires Nobre]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Da Silva Martins]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of peripheral intravenous catheter-related phlebitis: associated factors]]></article-title>
<source><![CDATA[Rev Enferm Ref]]></source>
<year>2018</year>
<volume>IV</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>127-38</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
